Ord Minnett rates EBO as Lighten -February 21, 2024 at 0831 pm EST - Marketscreener.com
X2S Stock | EUR 2.64 0.04 1.54% |
Roughly 55% of Sinopharm Group's stockholders are presently thinking to get in. The analysis of current outlook of investing in Sinopharm Group Co suggests that some traders are interested regarding Sinopharm Group's prospects. The current market sentiment, together with Sinopharm Group's historical and current headlines, can help investors time the market. In addition, many technical investors use Sinopharm Group stock news signals to limit their universe of possible portfolio assets.
Sinopharm Group stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Sinopharm daily returns and investor perception about the current price of Sinopharm Group Co as well as its diversification or hedging effects on your existing portfolios.
Sinopharm |
Ord Minnett rates EBO as Lighten -February 21, 2024 at 0831 pm EST Marketscreener.com
Read at news.google.com
Sinopharm Group Fundamental Analysis
We analyze Sinopharm Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sinopharm Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sinopharm Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earnings To Growth
Price To Earnings To Growth Comparative Analysis
Sinopharm Group is rated first in price to earnings to growth category among its peers. PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Sinopharm Group Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sinopharm Group stock to make a market-neutral strategy. Peer analysis of Sinopharm Group could also be used in its relative valuation, which is a method of valuing Sinopharm Group by comparing valuation metrics with similar companies.
Peers
Sinopharm Group Related Equities
X2S1 | SINOPHARM GROUP | 1.55 | ||||
X2S | Sinopharm Group | 1.54 | ||||
CLH | Cardinal Health | 0.94 | ||||
59Z | MEDIPAL HOLDINGS | 0.70 | ||||
ABG | AmerisourceBergen | 0.37 | ||||
S1R | Shanghai Pharmaceuticals | 0.63 | ||||
PBV | Prestige Consumer | 0.66 | ||||
PD2 | Patterson Companies | 1.34 | ||||
HS2 | Henry Schein | 2.60 |
Complementary Tools for Sinopharm Stock analysis
When running Sinopharm Group's price analysis, check to measure Sinopharm Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinopharm Group is operating at the current time. Most of Sinopharm Group's value examination focuses on studying past and present price action to predict the probability of Sinopharm Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinopharm Group's price. Additionally, you may evaluate how the addition of Sinopharm Group to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |